MedTrace Logo

Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults

NCT00557583 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2013-12-31

No results posted yet for this study

Summary

The study will evaluate the safety and pharmacokinetics of single doses of VBY-376 in healthy subjects.

Conditions

  • Chronic Hepatitis C Infection

Interventions

DRUG

VBY 376

Doses of 50mg and higher or placebo will be evaluated.

Sponsors & Collaborators

  • Virobay Inc.

    lead INDUSTRY

Principal Investigators

  • Stephen D Flach, MD · Covance CRU

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00557583 on ClinicalTrials.gov